Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Momentum is so poor with so many stocks at the moment and this is one of them big time. Even if this team meeting event is very positive tomorrow there will be a small spike and it will likely dissipate. Need to see a concerted turnaround in figures and a weakened covid outlook before these shares turnaround. Nonetheless, I bought another tranch at 1199p to bring my average down to 1264p
I’ve been an investor for a couple of years but have to say waiting for this to take off is testing to say the least. Why has this dropped 10% plus to 268 when tech shares in general are unaffected by covid? It’s said Spirent are in a growing market for 5g network testing and sit on a reasonable forward pe of 20. Jeffries price target of 340p is a long way off. I am trying to decide whether to top up or get out and invest elsewhere. What do you fellow investors make of the recent weakness and failure to break the 300p barrier?
Ashtead is a solid growth share that in my view has further to go as the sunbelt 3.0 expansion plan keeps on going . There is still vast amounts of market share in the states up for grabs. AHT has been my most profitable investment over the last 2 years. They just go about their business quietly and professionally and these boards are so quiet which is surprising. I guess the lack of wild swings mean no day traders on here. Long May it continue!
Even with a bit of profit taking the market is obviously still sceptical and concerned by the near term challenges for SN, as there is no momentum when the rest of the market in general is hitting highs. Momentum is just fizzling out and I can see this dropping back below £13 very soon unfortunately. More opportunities to snap up some more I guess!
I am taking up another stake after selling previously by drip feeding in as the price drops to even out my average. I have no long term concerns that Dark will not be a success or a takeover target. So I am not worried by this volatility and view it as an opportunity. When the tide turns it will be swift imho
Motley fool recommendation today
Smith & Nephew’s (LSE: SN) another FTSE 100 stock I believe provides brilliant value today. In fact, I’d buy it before the healthcare giant releases third-quarter financials on November 4. I think another share-price-boosting update could be coming down the pipe.
Smith & Nephew — which is primarily known for manufacturing artificial limbs and joints — has traded strongly since Covid-19 eased in many regions and elective surgery procedures picked up again. Most recent financials showed revenues rocketed 48.2% in the second quarter, up from 11.5% in quarter one.
City analysts think Smith & Nephew’s earnings will also leap 21% in 2022. This leaves it trading on a forward PEG ratio of just 0.8. This represents excellent value, given that global healthcare spending is poised to rise strongly in the years ahead.
I also think the company’s role in developing surgical robotic technology will pay off handsomely. I’d buy Smith & Nephew despite the threat posed to elective surgery rates by the ongoing pandemic.
Adastra you are clearly backing SN hook, line and sinker. What percentage of your portfolio do you have in SN? I am considering buying heavily early next week and going long on these, my other major holding is Ashtead